Antiangiogenic Cancer Therapy: 1st Edition (Hardback) book cover

Antiangiogenic Cancer Therapy

1st Edition

Edited by Darren W. Davis, Roy S. Herbst, James L. Abbruzzese

CRC Press

864 pages | 109 B/W Illus.

Purchasing Options:$ = USD
Hardback: 9780849327995
pub: 2007-07-25
$290.00
x
eBook (VitalSource) : 9780429122200
pub: 2007-07-25
from $145.00


FREE Standard Shipping!

Description

Top Investigators Explore the Complexities of Angiogenesis Cancer Research

The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.

Compiles the results of four decades of progress

Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject.

  • Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment.
  • Covers specific molecular targets for inhibiting angiogenesis in cancer therapy.    
  • Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors.
  • Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers.
  • This volume celebrates progress made in four decades, and more importantly, it provides a clear indication of the complex biology that needs further investigation to realize the possibilities envisioned for this beneficial therapeutic modality.

    Reviews

    "… a timely and worthwhile study of the complexities of the clinical application of angiogenesis inhibitors. … the most comprehensive of its kind, is nicely tempered in its assessments of both the triumphs of antiangiogenic tumor therapy and the gaps in knowledge that impede further successful treatments. The editors and contributors of this book … are leaders in the field. The topics covered … are well chosen and present the reader with balanced discussions … . This authoritative book should be required reading for anyone interested in tumor angiogenesis."

    — Joshua I. Greenberg, M.D. & David A. Cheresh, Ph.D., University of California, San Diego, La Jolla in The New England Journal of Medicine, July 2008

    "It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject."

    – In Anticancer Research, 2009, Vol. 29

    Table of Contents

    Table of Contents

    PART I. ANGIOGENESIS IN CANCER 

    Strategies to Prolong the Nonangiogenic Dormant State of Human Cancer; George N. Naumov and Judah Folkman

    Vascular Endothelial Growth Factor: Basic Biology and Clinical Implications; Napoleone Ferrara

    Angiogenesis in Solid Tumors; Rakesh K. Jain and Dan G. Duda

    Pathophysiologic Role of VEGF in Hematologic Malignancies; Klaus Podar, Shaji Kumar, Dharminder Chauhan, and Kenneth C. Anderson

    Tumor Microenvironment and Angiogenesis; Cheryl H. Baker and Isaiah J. Fidler

    PART II. TARGETING ANGIOGENESIS FOR CANCER THERAPY 

    Tyrosine Kinase Inhibitors of Angiogenesis; Janessa J. Laskin and Alan B. Sandler

    Development of Antiangiogenic Monoclonal Antibodies for Cancer Therapy; Zhenping Zhu and Daniel J. Hicklin

    Targeting Fibroblast Growth Factor/Fibroblast Growth Factor Receptor System in Angiogenesis; Marco Rusnati and Marco Presta

    Development of the VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and Discovery of the Next Generation of Angiogenesis Targets; John S. Rudge, Gavin Thurston, Samuel Davis, Nicholas Papadopoulos, Nicholas W. Gale, Stanley J. Wiegand, and George D. Yancopoulos

    Proteinases and Their Inhibitors in Angiogenesis; Yves A. DeClerck, Khalid Bajou, and Walter E. Laug

    Prostaglandins and COX-2: Role in Antiangiogenic Therapy; Kristin Hennenfent, Daniel Morgensztern, and Ramaswamy Govindan

    Integrins, Adhesion, and Coadhesion Inhibitors in Angiogenesis; Abebe Akalu and Peter C. Brooks

    Conventional Therapeutics with Antiangiogenic Activity; Christian Hafner, Thomas Vogt, and Albrecht Reichle

    Vascular Disrupting Agents; David J. Chaplin, Graeme J. Dougherty, and Dietmar W. Siemann

    Vascular and Hematopoietic Stem Cells as Targets for Antiangiogenic Therapy; Shahin Rafii

    Genetic Strategies for Targeting Angiogenesis; Anita Tandle, Mijung Kwon, and Steven K. Libutti

    Identification of New Targets Using Expression Profiles; Thomas R. Burkard, Zlatko Trajanoski, Maria Novatchkova, Hubert Hackl, and Frank Eisenhaber

    PART III. TRANSLATING ANGIOGENESIS INHIBITORS TO THE CLINIC

    Clinical Trial Design and Regulatory Issues; Ramzi N. Dagher and Richard Pazdur

    Surrogate Markers for Antiangiogenic Cancer Therapy; Darren W. Davis

    Noninvasive Surrogates; Bruno Morgan and Mark A. Horsfield

    Pharmacodynamic Markers in Tissues; Darren W. Davis

    Blood-Based Biomarkers for VEGF Inhibitors; Amado J. Zurita, Hua-Kang Wu, and John V. Heymach

    PART IV. TREATMENT OF SPECIFIC CANCERS WITH ANGIOGENESIS INHIBITORS

    Antiangiogenic Therapy for Colorectal Cancer; Paulo M. Hoff and Everardo D. Saad

    Combined Modality Therapy of Rectal Cancer; Christopher G. Willett and Dan G. Duda

    Antiangiogenic Therapy for Breast Cancer; Pablo M. Bedano, Brian P. Schneider, Kathy D. Miller, and George W. Sledge Jr.

    Antiangiogenic Therapy for Lung Malignancies; David J. Stewart

    Antiangiogenic Therapy for Prostate Cancer; Leslie K. Walker, Glenn Liu, and George Wilding

    Antiangiogenic Therapy for Hematologic Malignancies; Karen W.L. Yee and Francis J. Giles

    Antiangiogenic Therapy for Gliomas; Heinrich Elinzano and Howard A. Fine

    Antiangiogenic Therapy for Kaposi’s Sarcoma; Henry B. Koon, Liron Pantanowitz, and Bruce J. Dezube

    Antiangiogenic Therapy for Melanoma; Keith Dredge and Angus G. Dalgleish

    Sunitinib and Renal Cell Carcinoma; Robert J. Motzer and Sakina Hoosen

    Index

    Subject Categories

    BISAC Subject Codes/Headings:
    MED062000
    MEDICAL / Oncology
    MED071000
    MEDICAL / Pharmacology
    SCI017000
    SCIENCE / Life Sciences / Cytology